Analogs of parathyroid hormone

This application is a continuation application of U.S. application Ser. No. 11/094,662, filed Mar. 30, 2005, which is a divisional application of U.S. application Ser. No. 10/289,519, filed Nov. 6, 2002, now issued as U.S. Pat. No. 6,921,750, which is a continuation of U.S. application Ser. No. 09/399,499, filed Sep. 20, 1999, now issued as U.S. Pat. No. 6,544,949, which is a continuation-in-part of both U.S. application Ser. No. 08/779,768, filed Jan. 7, 1997, now issued as U.S. Pat. No. 5,969,095 and U.S. application Ser. No. 09/341,217, filed Nov. 22, 1999, now abandoned, which is the national phase application of International Application No. PCT/US97/22498, filed Dec. 8, 1997, which is a continuation-in-part of U.S. application Ser. No. 08/813,534, filed Mar. 7, 1997, now issued as U.S. Pat. No. 5,955,574, which is a continuation-in-part of U.S. application Ser. No. 08/779,768, filed Jan. 7, 1997, now issued as U.S. Pat. No. 5,969,095, which is a continuation-in-part of U.S. application Ser. No. 08/626,186, filed Mar. 29, 1996, now issued as U.S. Pat. No. 5,723,577, which claims the benefit of priority of U.S. Provisional Application No. 60/003,305, filed Sep. 6, 1995 and U.S. Provisional Application No. 60/001,105, filed Jul. 13, 1995. The content of all the prior applications are incorporated herein by reference in their entirety.

Parathyroid hormone (“PTH”) is a polypeptide produced by the parathyroid glands. The mature circulating form of the hormone is comprised of 84 amino acid residues. The biological action of PTH can be reproduced by a peptide fragment of its N-terminus (e.g. amino acid residues 1 through 34). Parathyroid hormone-related protein (“PTHrP”) is a 139 to 173 amino acid-protein with N-terminal homology to PTH. PTHrP shares many of the biological effects of PTH including binding to a common PTH/PTHrP receptor. Tregear, et al., Endocrinal., 93:1349 (1983). PTH peptides from many different sources, e.g., human, bovine, rat, chicken, have been characterized. Nissenson, et al., Receptor, 3:193 (1993).

PTH has been shown to both improve bone mass and quality, Dempster, et al., Endocrine Rev., 14:690 (1993); and Riggs, Amer. J. Med., 91 (Suppl. 5B):37S (1991). The anabolic effect of intermittently administered PTH has been observed in osteoporotic men and women either with or without concurrent antiresorptive therapy. Siovik, et al., J. Bone Miner. Res., 1:377 (1986); Reeve, et al., Br. Med. J., 301:314 (1990); and Hesch, R-D., et al., Calcif. Tissue Int'l, 44:176 (1989).

In one aspect, the invention features a peptide of the formula (I).

wherein

A 1 is Ser, Ala, or Dap; A 2 is Ser, Thr; or Aib; A 5 is Leu, Nle, Ile, Cha, β-Nat, Trp, Pal, Acc, Phe or p-X-Phe, in which X is OH, a halogen, or CH 3 ; A 7 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Acc, Phe, or p-X-Phe, in which X is OH, a halogen, or CH 3 ; A 8 is Met, Nva, Leu, Val, Ile, Cha, Acc, or Nle; A 11 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Acc, Phe or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 12 is Gly, Acc, or Aib; A 15 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Acc, Phe, or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 16 is Ser, Asn, Ala, or Aib; A 17 is Ser, Thr, or Aib; A 18 is Met, Nva, Leu, Val, Ile, Nle, Acc, Cha, or Aib; A 19 is Glu or Aib; A 21 is Val, Acc, Cha, or Met; A 22 is Acc or Glu; A 23 is Trp, Acc, or Cha; A 24 is Leu, Acc, or Cha; A 27 is Lys, Aib, Leu, hArg, Gln, Acc, or Cha; A 28 is Leu, Acc, or Cha; A 29 is Gln, Acc, or Aib; A 30 is Asp or Lys; A 31 is Val, Leu, Nle, Acc, Cha, or deleted; A 32 is His or deleted; A 33 is Asn or deleted; A 34 is Phe, Tyr, Amp, Aib, or deleted;

each of R 1 and R 2 is, independently, H, C 1-12 alkyl, C 7-20 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; or one and only one of R 1 and R 2 is COE 1 in which E 1 is C 1-12 alkyl, C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxy-phenylalkyl, or C 11-20 hydroxynaphthylalkyl; and

R 3 is OH, NH 2 , C 1-12 alkoxy, or NH—Y—CH 2 —Z in which Y is a C 1-12 hydrocarbon moiety and Z is H, OH, CO 2 H, or CONH 2 ;

provided that at least one of A 5 , A 7 , A 8 , A 11 , A 12 , A 15 , A 18 , A 21 , A 22 , A 23 , A 27 , A 26 , A 29 , and A 31 is Acc; or a pharmaceutically acceptable salt thereof.

A preferred embodiment of the immediately foregoing peptide is where A 3 is Ser; A 5 is Ile or Acc; A 7 is Leu, Acc, or Cha; A 8 is Acc, Met. Nva, Leu, Val, Ile, or Nle; A 11 is Leu, Acc, or Cha; A 12 is Acc or Gly; A 15 is Leu, Acc, or Cha; A 16 is Asn or Aib; A 17 is Ser or Aib; A 18 is Acc, Met, or Nle; A 21 is Val or Acc; A 27 is Lys, hArg, Acc, or Cha; A 31 is Val, Leu, Nle, Acc, or Cha; A 32 is His; A 33 is Asn; A 34 is Phe, Tyr, Amp, or Aib; or a pharmaceutically acceptable salt thereof.

A preferred embodiment of the immediately foregoing peptide, designated Group B, is where A 5 is Ile or Ahc; A 7 is Leu, Ahc, or Cha; A 8 is Ahc, Met, or Nle; A 11 is Leu, Ahc, or Cha; A 12 is Ahc or Gly; A 15 is Leu, Ahc, or Cha; A 18 is Met or Ahc; A 21 is Val or Ahc; A 22 is Glu or Ahc; A 23 is Trp, Ahc, or Cha; A 24 is Leu, Ahc, or Cha; A 27 is Lys, hArg, Ahc, or Cha; A 28 is Leu, Ahc, or Cha; A 29 is Gln, Ahc, or Aib; A 31 is Val, Leu, Nle, Ahc, or Cha; R 1 is H; R 2 is H; and R 3 is NH 2 ; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of Group B is where at least one of A 7 , A 11 , A 15 , A 23 , A 24 , A 27 , A 28 , or A 31 is Cha.

Another preferred group of peptides of Group B is where at least one of A 16 , A 17 , A 19 , A 29 , or a 34 is Aib.

Preferred peptides of formula (I) are [Ahc 7 11 ]hPTH(1-34)NH 2 ; [Ahc 7 11 , Nle 8 18 , Tyr 34 ]hPTH(1-34)NH 2 ; [Ahc 11 ]hPTH(1-34)NH 2 ; [Ahc 7 11 15 ]hPTH(1-34)NH 2 ; [(Ahc 7 ]hPTH(1-34)NH 2 ; [Ahc 23 ]hPTH(1-34)NH 2 ; [Ahc 24 ]hPTH(1-34)NH 2 ; [Nle 8 18 , Ahc 27 ]hPTH(1-34)NH 2 ; [Ahc 28 ]hPTH(1-34)NH 2 ; [Ahc 31 ]hPTH(1-34)NH 2 ; [Ahc 24 28 31 ]hPTH(1-34)NH 2 ; [Ahc 24 28 31 , Lys 30 ]hPTH(1-34)NH 2 ; [Ahc 28 31 ]hPTH(1-34)NH 2 ; [Ahc 15 ]hPTH(1-34)NH 2 ; [Ahc 24 27 , Aib 29 , Lys 30 ]hPTH(1-34)NH 2 ; [Ahc 24 27 , Aib 29 , Lys 30 , Leu 31 ]hPTH(1-34)NH 2 ; [Ahc 5 ]hPTH(1-34)NH 2 ; [Ahc 12 ]hPTH(1-34)NH 2 ; [Ahc 27 ]hPTH(1-34)NH 2 ; [Ahc 29 ]hPTH(1-34)NH 2 ; [Ahc 24 27 ]hPTH(1-34)NH 2 ; [Ahc 24 27 , Aib 29 ]hPTH(1-34)NH 2 ; [Ahc 24 , Aib 29 ]hPTH(1-34)NH 2 ; [Ahc 27 , Aib 29 ]hPTH(1-34)NH 2 ; [Ahc 18 ]hPTH(1-34)NH 2 ; [Ahc 8 ]hPTH(1-34)NH 2 ; [Ahc 18 27 , Aib 29 ]hPTH(1-34)NH 2 ; or [Ahc 18 24 27 , Aib 29 ]hPTH(1-34)NH 2 ; [Ahc 22 , Leu 27 , Aib 29 ]hPTH(1-34)NH 2 ; [Ahc 24 , Leu 27 , Aib 29 ]hPTH(1-34)NH 2 ; [Ahc 22 ]hPTH(1-34)NH 2 ; and [Ahc 22 , Aib 29 ]hPTH(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

The invention also features peptides of the following formulae: [Cha 22 23 , Glu 25 , Lys 26 30 , Leu 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Cha 22 23 , Glu 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34) NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 26 , Aib 29 , Nle 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 30 31 , Lys 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 30 31 , Lys 26 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Lys 26 , Nle 30 ]hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 23 28 31 , His 14 , Cha 15 , Glu 22 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Cha 23 , Lys 26 , Leu 28 31 , Aib 29 , Nle 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 23 , Glu 25 , Lys 26 30 , Leu 28 31 Aig 29 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 29 , Lys 25 , Nle 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 15 ]hPTHrP(1-34)NH 2 ; [Cha 7 8 15 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Cha 23 , Aib 25 29 , Lys 26 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Cha 23 , Aib 25 29 , Lys 26 , Leu 28 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 , Aib 25 29 , Lys 26 ]hPTHrP(1-34)NH 2 ; [Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Cha 23 , Lys 26 , Leu 28 31 , Aib 29 , Nle 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Cha 23 , Lys 26 30 , Aib 29 , Leu 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 26 , Aib 29 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Aib 26 29 , Lys 30 ]hPThrP(1-34)NH 2 ; [Glu 22 25 , Cha 23 , Lys 26 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Cha 23 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Cha 23 , Lys 26 30 , Leu 28 , Aib 29 ]hPTHrP(1-34)NH 2 or [Leu 27 Aib 29 ]hPTH(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

The following are examples of the peptides of the invention covered by the above formula: [Glu 22 25 , Leu 23 28 , Lys 26 30 , Aib 29 , Ahc 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Ahc 23 , Lys 26 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 26 30 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Lys 26 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 , Lys 26 30 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Ahc 24 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Aib 25 , Lys 26 30 , Ahc 27 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Aib 25 29 , Lys 26 30 , Ahc 27 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 31 , Glu 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 31 , Lys 26 30 , Ahc 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Ahc 23 , Glu 25 , Lys 26 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 24 27 , Leu 23 28 31 , Glu 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Ahc 24 27 , Glu 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Ahc 24 27 , Lys 25 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 18 24 27 , Glu 22 , Cha 23 , Lys 25 26 , Leu 28 , Aib 29 (]hPTHrP(1-34)NH 2 ; [Glu 22 , Cha 23 , Ahc 24 , Lyc 25 26 , Leu 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 26 , Ahc 27 , Aib 29 , Nle 30 ]hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 , Met 8 , Asn 10 , His 14 , Glu 22 25 , Leu 23 28 31 , Lys 26 30 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 23 28 31 , His 14 , Cha 15 , Glu 22 25 , Lys 26 30 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Ahc 23 , Glu 25 , Lys 26 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Ahc 23 , Aib 25 29 , Lys 26 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 26 30 , Ahc 29 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Ahc 24) , Glu 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Ahc 24 27 , Glu 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Ahc 24 27 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 24 27 , Leu 23 28 31 , Glu 25 , Lys 26 30 , Aib 29 ]hPThrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Aib 25 29 , Lys 26 30 , Ahc 27 ]hPTHrP(1-34)NH 2 ; [Ahc 22 27 , Leu 23 28 31 , Aib 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Ahc 24 27 , Lys 25 26 30 , Aib 29 ]hPTHrP 1-34)NH 2 ; [Glu 22 , Leu 23 25 , Ahc 24 27 , Lys 25 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Cha 23 , Ahc 24 27 , Lys 25 25 30 , Leu 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Cha 23 , Ahc 24 27 , Lys 26 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Cha 23 , Ahc 24 27 , Lys 25 26 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Ahc 24 27 , Lys 25 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 , Ahc 24 27 , Lys 25 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Cha 23 , Ahc 24 27 , Lys 25 26 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Cha 23 , Ahc 24 27 , Lys 25 26 , Leu 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 , Lys 25 26 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Lys 25 26 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Lys 25 26 30 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 , Lys 25 26 30 , Ahc 27 , Aib 29 ]hPTHRP(1-34)NH 2 , [Glu 22 , Cha 23 , Ahc 24 , Lys 25 25 , Leu 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 26 , Aib 29 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Aib 22 29 , Leu 23 28 31 , Glu 25 , Lys 28 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Ahc 23 , Glu 25 29 , Lys 26 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Ahc 24 , Glu 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 30 , Ahc 27 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 31 , Glu 25 29 , Lys 26 30 , Ahc 28 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 29 , Glu 25 29 , Lys 26 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 , Glu 25 29 , Lys 26 30 , Ahc 31 , ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Ahc 23 , Aib 25 , Lys 26 30 , Leu 28 31 , ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 31 , Aib 25 , Lys 26 30 , Glu 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Ahc 24 , Aib 25 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 31 , Aib 25 ,Lys 26 30 , Ahc 28 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 , Aib 25 , Lys 26 30 , Ahc 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Aib 25 , Lys 25 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Lys 26 , Ahc 27 , Aib 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Ahc 24 , Lys 26 , Aib 30 ] hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 , Aib 30 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 , Glu 25 29 , Lys 26 30 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 , Lys 26 31 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 , Lys 26 30 31 , Ahc 27 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Cha 23 , Glu 25 , Lys 28 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Cha 23 , Lys 25 26 30 , Leu 28 31 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Cha 23 , Lys 25 26 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 , Lys 25 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 , Arg 25 , Lys 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 24 , Leu 23 28 31 , Glu 25 , Lys 28 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 24 , Leu 23 28 31 , Lys 25 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 24 , Leu 23 28 31 , Lys 25 25 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 24 , Leu 23 28 , Lys 25 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Ahc 22 24 , Leu 23 28 , Arg 25 , Lys 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Ahc 24 , Lys 25 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Ahc 24 , Lys 25 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 , Ahc 24 , Lys 25 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Ahc 24 , Arg 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Ahc 24 , Arg 25 , Lys 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 , Ahc 24 , Arg 25 , Lys 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Ahc 23 , Aib 25 29 , Lys 26 30 , Leu 28 31 ,]hPTHrP(1-34)NH 2 ; [Glu 22 , Ahc 23 , Aib 25 29 , Lys 26 , Leu 28 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Ahc 23 31 , Aib 25 29 , Lys 26 , Leu 28 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 , Aib 25 29 , Lys 26 30 , Ahc 31]hPTHrP( 1-34)NH 2 ; [Glu 22 , Leu 23 28 , Aib 25 29 , Lys 26 , Ahc 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 25 , Ahc 24 31 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; or [Glu 22 , Leu 23 28 , Ahc 24 31 , Lys 25 26 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Ahc 24 , Aib 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

In another aspect, the invention relates to peptide variants of PTH(1-34) of the following generic formula:

wherein

A 2 is Ser, Ala, or Dap; A 3 is Ser, Thr, or Aib; A 5 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe or p-X-Phe, in which X is OH, a halogen or CH 3 ; A 7 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe, or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 8 is Met, Nva, Leu, Val, Ile, Cha, or Nle; A 11 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe or p-X-Phe in which X is OH, a halogen or CH 3 ; A 12 is Gly or Aib; A 15 is Leu, Nle, Ile, Cha, β-Nal, Trp Pal, Phe, or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 16 is Ser, Asn, Ala or Aib; A 17 is Ser, Thr, or Aib; A 18 is Met, Nva, Leu, Val, lle, Nle, Cha or Aib; A 19 is Glu or Aib; A 21 is Val, Cha, or Met; A 23 is Trp or Cha; A 24 is Leu or Cha; A 27 is Lys, Aib, Leu, hArg, Gln, or Cha; A 28 is Leu or Cha; A 30 is Asp or Lys; A 31 is Val, Nle, Cha, or deleted; A 32 is His or deleted; A 33 is Asn or deleted; A 34 is Phe, Tyr, Amp, Aib or deleted; each of R 1 and R 2 is, independently, H, C 1-12 alkyl, C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; or one and only one of R 1 and R 2 is COE 1 in which E 1 is C 1-12 is alkyl, C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxy-phenylalkyl, or C 11-20 hydroxynaphthylalkyl; and R 3 is OH, NH 2 , C 1-12 alkoxy, or NH—Y—CH 2 —Z in which Y is a C 1-12 hydrocarbon moiety and Z is H, OH, CO 2 H, or CONH 2 ;

provided that (i) at least one of A 5 , A 7 , A 8 , A 11 , A 15 , A 18 , A 21 , A 23 , A 24 , A 27 , A 28 , and A 31 is Cha, or at least one of A 3 , A 12 , A 15 , A 17 , A 18 , A 19 , and A 34 is Aib; or that (ii) at least A 1 is Dap, A 7 is β-Nal, Trp, Pal, Phe, or p-X-Phe, A 15 is β-Nal, Trp, Pal, Phe, or p-X-Phe, A 27 is hArg, or A 31 is Nle; or a pharmaceutically acceptable salt thereof.

In another aspect, the invention relates to peptide variants of PTH(1-34) of the following formula (II):

wherein

A 1 is Ser, Ala, or Dap; A 3 is Ser, Thr or Aib; A 5 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe or p-X-Phe, in which X is OH, a halogen, or CH 3 ; A 7 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe, or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 8 is Mel, Nva, Leu, Val, Ile, Cha, or Nle; A 11 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe or p-X-Phe in whic X is OH, a halogen, or CH 3 ; A 12 is Gly or Aib; A 15 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe, or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 16 is Ser, Asn, Ala, or Aib; A 17 is Ser, Thr, or Aib; A 18 is Met, Nva, Leu, Val, Ile, Nle, Cha, or Aib; A 19 is Glu or Aib; A 21 is Val, Cha, or Met; A 23 is Trp or Cha; A 24 is Leu or Cha; A 27 is Lys, Aib, Leu, hArg, Gln, or Cha; A 28 is Leu or Cha; A 30 is Asp or Lys; A 31 is Val, Nle, Cha, or deleted; A 32 is His or deleted; A 33 is Asn or deleted; a 34 is Phe, Tyr, Amp, Aib, or deleted; each of R 1 and R 2 is, independently, H, C 1-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; or one and only one of R 1 and R 2 is COE 1 in which E 1 is C 1-12 alkyl C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxy-phenylalkyl, or C 11-20 hydroxynaphthylalkyl; and R 3 is OH, NH 2 , C 1-12 alkoxy, or NH—Y—CH 2 —Z in which Y is a C 1-12 hydrocarbon moiety and Z is H, OH, CO 2 H, or CONH 2 ;

provided that (i) at least one of A 5 , A 7 , A 8 , A 11 , A 15 , A 18 , A 21 , A 23 , A 24 , A 27 , A 28 , and A 31 is Cha, or at least one of A 3 , A 12 , A 16 , A 17 , A 18 , A 19 , and a 34 is Aib; and the peptide is not [Aib 12 , Tyr 34 ]hPTH(1-34)NH 2 , or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of formula (II), designated Group (i) is where at least one of A 7 , a 11 , A 15 , A 23 , A 24 , A 27 , A 28 , and A 31 is Cha; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of Group (i), designated Group (ii) is where A 3 is Ser; A 5 is Ile; A 7 is Leu or Cha; A 8 is Met, Nva, Leu, Val, Ile, or Nle; A 11 is Leu or Cha; A 12 is Gly; A 15 is Leu or Cha; A 16 is Asn or Aib; A 17 is Ser; A 18 is Met or Nle; A 21 is Val; A 27 is Lys, hArg, or Cha; A 32 is His; A 31 is Val, Nle, or Cha; A 33 is Asn; A 34 is Phe, Tyr, amp, or Aib; R 1 is H; R 2 is H; and R 3 is NH 2 ; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of Group (ii), designated Group (iii), is where at least one of A 7 and A 11 is Cha; or a pharmaceutically acceptable salt thereof.

Preferred peptides of Group (iii) are [Cha 7 11 ]hPTH(1-34)NH 2 , [Cha 7 11 , Nle 8 18 , Tyr 34 ]hPTH(1-34)NH 2 ; [Cha 11 ]hPTH(1-34)NH 2 ; [Cha 7 11 15 ]hPTH(1-34)NH 2 ; and [Cha 7 ]hPTH(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

Another preferred group of peptides of Group (ii), designated Group (iv), is where at least one of A 15 , A 23 , A 24 , A 27 , A 28 , and A 31 is Cha; or a pharmaceutically acceptable salt thereof.

Preferred peptides of Group (iv) are [Cha 23 ]hPTH(1-34)NH 2 , [Cha 24 ]hPTH(1-34)NH 2 , [Nle 8 18 , Cha 27 ]hPTH(1-34)NH 2 , [Cha 28 ]hPTH(1-34)NH 2 , [Cha 31 ]hPTH(1-34)NH 2 , [Cha 24 28 31 ]hPTH(1-34)NH 2 ; [Cha 24 28 31 , Lys 30 ]hPTH(1-34)NH 2 ; [Cha 28 31 ]hPTH(1-34)NH 2 ; and [Cha 15 ]hPTH(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

Another preferred group of peptides of formula (II), designated Group (v), is where at least one of A 3 , A 12 , A 16 , A 17 , A 18 , A 19 , and A 34 is Aib; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of Group (v), designated Group (vi), is where A 3 is Ser or Aib; A 5 is Ile; A 7 is Leu or Cha; A 8 is Met, Nva, Leu, Val, Ile, or Nle; A 11 is Leu or Cha; A 15 is Leu or Cha; A 15 is Asn or Aib; A 18 is Met, Aib, or Nle; A 21 is Val; A 27 is Lys, Aib, Leu, hArg, or Cha; A 31 is Val, Nle, or Cha; A 32 is His; A 33 is Asn; A 34 is Phe, Tyr, Amp, or Aib; R 1 is H; R 2 is H; and R 3 is NH 2 or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of Group (vi), designated Group (vii), is where at least one of A 3 , A 12 , A 16 , A 17 , A 19 , and A 34 is Aib; or a pharmaceutically acceptable salt thereof.

Preferred peptides of Group (vii) are [Aib 16 ]hPTH(1-34)NH 2 , [Aib 19 ]hPTH(1-34)NH 2 , [Aib 34 ]hPTH(1-34)NH 2 ; [Aib 15 19 ]hPTH(1-34)NH 2 ; [Aib 3 ]hPTH(1-34)NH 2 ; [Aib 17 ]hPTH(1-34)NH 2 ; and [Aib 12 ]hPTH(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

Another preferred group of peptides of formula (II), designated Group (viii), is where at least one of A 7 , A 11 , A 15 , A 23 , A 24 , A 27 , a 28 , and A 31 is Cha and at least one of A 3 , A 12 , A 16 , A 17 , A 18 , A 19 , and a 34 is Aib; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of Group (viii), designated Group (ix), is where A 3 is Ser or Aib; A 5 is Ile; A 7 is Leu or Cha; A 8 is Met, Nva, Leu, Val, Ile, or Nle; a 11 is Leu or Cha; A 15 is Leu or Cha; A 16 is Asn or Aib; A 18 is Met, Aib, or Nle; A 21 is Val; A 27 is Lys, Aib, Leu, hArg, or Cha; A 31 is Val, Nle, or Cha; A 32 is His; A 33 is Asn; A 34 is Phe, Tyr, Amp, or Aib; R 1 is H; R 2 is H; and r 3 is NH 2 ; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of Group (ix), designated Group (x), is where at least one of A 7 and A 11 is Cha and at least one of A 16 , A 19 , and A 34 is Aib; or a pharmaceutically acceptable salt thereof.

Preferred peptides of Group (x) are [Cha 7 11 , Nle 8 18 , Aib 16 19 , Tyr 34 ]hPTH(1-34)NH 2 , [Cha 7 11 , Nle 8 18 31 , Aib 16 19 , Tyr 34 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Aib 19 ]hPTH(1-34)NH 2 , [Cha 7 11 , Aib 16 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Nle 8 18 , Aib 34 ]hPTH(1-34)NH 2 ; or [Cha 7 11 , Aib 19 , Lys 30 ]hPTH(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

Another preferred group of peptides of Group (ix), designated Group (xi), is where at least one of A 24 , A 28 , and A 31 is Cha and at least one of A 15 and A 17 is Aib; or a pharmaceutically acceptable salt thereof.

Preferred peptides of Group (xi) are [Cha 28 , Nle 8 18 , Aib 16 19 , Tyr 34 ]hPTH(1-34)NH 2 , and [Cha 28 , Aib 18 19 ]PTH(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention is directed to a peptide of the formula (III):

wherein

A 1 is Ser, Ala or Dap; A 3 is Ser, Thr, or Aib; A 5 is Leu, Nle, Cha, β-Nal, Trp, Pal, Phe or p-X-Phe, in which X is OH, a halogen, or CH 3 ; A 7 is Leu, Nle, Cha, β-Nal, Trp, Pal, Phe, or p-X-Phe in which X is H, OH, a halogen, or CH 3 ; A 8 is Met, Nva, Leu, Val, Ile, Cha, or Nle; A 11 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 12 is Gly or Aib; A 15 is Leu, Nle, Ile, Cha, β-Nal, Trp, Pal, Phe, or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 16 is Ser, Asn, Ala, or Aib; A 17 is Ser, Thr, or Aib; A 18 is Met, Nva, Leu, Val, Ile, Nle, Cha, or Aib; A 19 is Glu or Aib; A 21 is Val, Cha, or Met; A 23 is Trp or Cha; A 24 is Leu or Cha; A 27 is Lys, Aib, Leu, hArg, Gln, or Cha; A 28 is Leu or Cha; A 30 is Asp or Lys; a 31 is Val, Nle, Cha, or deleted; A 32 is His or deleted; A 33 Asn or deleted; A 34 is Phe, Tyr, Amp, Aib, or deleted; each of R 1 and R 2 is, independently, H, C 1-12 alkyl, C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; or one and only one of R 1 and R 2 is COE 1 in which E 1 is C 1-12 alkyl, C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxy-phenylalkyl, or C 11-20 hydroxynaphthylalkyl; R 3 is OH, NH 2 , C 1-12 alkoxy, or NH—Y—CH 2 —Z in which Y is a C 1-12 hydrocarbon moiety and Z is H, OH, CO 2 H, or CONH 2 ;

provided that at least A 1 is Dap, A 7 is β-Nal, Trp, Pal, Phe, or p-X-Phe; A 15 is β-Nal, Trp, Pal, Phe, or p-X-Phe, A 27 is hArg, or A 31 is Nle; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of formula (III) is where A 1 is Ser, Gly, or Dap; A 3 is Ser or Aib; A 8 is Met, Nva, Leu, Val, Ile, or Nle; A 18 is Asn or Aib; A 18 is Met, Aib, or Nle; A 21 is Val; A 27 is Lys, Aib, Leu, hArg, or Cha; A 31 is Val, Nle, or Cha; A 32 is His; A 33 is Asn; A 34 is Phe; Tyr, Amp, or Aib; R 1 is H; R 2 is H; and R 3 is NH 2 ; or a pharmaceutically acceptable salt thereof.

Preferred peptides of the immediately foregoing peptides are [Nle 31 ]hPTh(1-34)NH 2 ; [hArg 27 ]hPTH(1 -34)NH 2 , and [Dap 1 Nle 8 18 , Tyr 34 ]hPTH(1-34)NH 2 ; or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention is directed to a peptide of the formula (IV):

wherein

A 2 is Ala, Ser, or Dap; A 3 is Ser or Aib; A 5 is His, Ile, or Cha; A 7 is Leu, Cha, Nle, β-Nal, Trp, Pal, Phe, or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 8 is Leu, Met, or Cha; A 10 is Asp or Asn; A 11 is Lys, Leu, Cha, Phe, or β-Nal; A 12 is Gly or Aib; A 14 is Ser or His; A 15 is Ile, or Cha; A 16 is Gln or Aib; A 17 is Asp or Aib; A 18 is Leu, Aib, or Cha; A 19 is Arg or Aib; A 22 is Phe, Glu, Aib, or Cha; A 23 is Phe, Leu, Lys, or Cha; A 24 is Leu, Lys, or Cha; A 25 is His, Aib, or Glu; A 26 is His, Aib, or Lys; A 27 is Leu, Lys, or Cha; A 28 is Ile, Leu, Lys, or Cha; A 29 is Ala, Glu, or Aib; A 30 is Glu, Cha, Aib, or Lys; A 31 is Leu, Cha, Lys, or deleted; A 32 is His or deleted; A 33 is Thr or deleted; A 34 is Ala or deleted; each of R 1 and R 2 is, independently, H, C 1-12 alkanyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 , hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; or one and only one of R 1 and R 2 is COE 1 in which E 1 is C 1-12 alkyl, C 2-12 alkyl, C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; and R 3 is OH, NH 2 , C 1-12 alkoxy, or NH—Y—CH 2 —Z in which Y is a C 1-12 hydrocarbon moiety and Z is H, OH, CO 2 H or CONH 2 ;

provided that at least one of A 5 , A 7 , A 8 , A 11 , A 15 , A 18 , A 22 , A 23 , A 24 , A 27 , A 28 , A 30 , or A 31 is Cha or at least one of A 3 , A 12 , A 16 , A 17 , A 18 , A 19 , A 22 , A 25 , A 26 , A 29 , A 30 , or A 34 is Aib; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of formula (V) is where A 22 is Phe or Cha; A 23 is Phe or Cha; A 25 is His; A 26 is His; A 27 is Leu or Cha; A 29 is Ala; A 30 is Glu or Lys; A 31 is Ile or Cha; A 32 is His; A 33 is Thr; and A 34 is Ala; or a pharmaceutically acceptable salt thereof. Two preferred groups of peptides of the immediately foregoing group of peptides is where at least one of A 7 and A 11 is Cha; or where at least one of A 15 or A 19 is Aib; or a pharmaceutically acceptable salt thereof.

Another preferred group of peptides of formula (IV), is where A 22 is Glu, Aib, or Cha; A 23 is Leu, Lys, or Cha; A 25 is Aib or Glu; A 25 is Aib or Lys; A 28 is Leu, Lys, or Cha; A 29 is Glu or Aib; A 30 is Cha, Aib, or Lys; A 31 is Leu, Cha, or Lys; A 32 is His; A 33 is Thr; and A 34 is Ala; or a pharmaceutically acceptable salt thereof. Two preferred groups of peptides of the immediately foregoing group of peptides is where at least one of A 7 and A 11 is Cha; or where at least one of A 16 or A 19 is Aib; or a pharmaceutically acceptable salt thereof.

In another aspect, this invention is directed to a peptide of the formula (V):

wherein

A 1 is Ala, Ser or Dap; A 3 is Ser or Aib; A 5 is His, Ile or Cha; A 7 is Leu, Cha, Nle, η-Nal, Trp, Pal, Phe, or p-X-Phe in which X is OH, a halogen or CH 3 ; A 8 is Leu, Met or Cha; A 10 is Asp or Asn; A 11 is Lys, Leu, Cha, Phe or β-Nal; A 12 is Gly or Aib; A 14 is Ser or His; A 15 is Ile or Cha; A 16 is Gln or Aib; A 17 is Asp or Aib; A 18 is Leu, Aib or Cha; A 19 is Arg or Aib; A 22 is Phe, Glu, Aib, Acc or Cha; A 23 is Phe, Leu, Lys, Acc or Cha; A 24 is Leu, Lys, Acc or Cha; A 25 is His, Aib or Glu; A 25 is His, Aib or Lys; A 27 is Leu, Lys, Acc or Cha; A 28 is Ile, Leu, Lys, Acc or Cha; A 29 is Ala, Glu or Aib; A 30 is Glu, Cha, Aib, Acc or Lys; A 31 is Ile, Leu, Cha, Lys, Acc or deleted; A 32 is His or deleted; A 33 is Thr or deleted; A 34 is Ala or deleted; each of R 1 and R 2 is, independently, H, C 1-12 alkanyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 , hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; or one and only one of R 1 and R 2 is COE 1 in which E 1 is C 1-12 alkyl, C 2-12 alkyl, C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; and R 3 is OH, NH 2 , C 1-12 alkoxy, or NH—Y—CH 2 —Z in which Y is a C 1-12 hydrocarbon moiety and Z is H, OH, CO 2 H or CONH 2 ;

provided that at least one of A 23 , A 24 , A 27 , A 28 , or A 31 is Lys; or a pharmaceutically acceptable salt thereof.

A preferred group of peptides of formula (V) is where A 22 is Glu, Aib, Acc, or Cha; A 23 is Leu, Lys, Acc or Cha; A 25 is Aib or Glu; A 26 is Aib or Lys; A 28 is Leu, Lys, Acc, or Cha; A 29 is Glu or Aib; A 30 is Cha, Aib, Acc, or Lys; A 31 is Leu, Cha, Acc, or Lys; A 32 is His; A 32 is Thr; and A 34 Ala; or a pharmaceutically acceptable salt thereof. Two preferred groups of peptides of the immediately foregoing group of peptides is where at least one of A 7 and A 11 is Cha; or where at least one of A 16 or A 19 is Aib; or a pharmaceutically acceptable salt thereof.

The following are examples of peptides of this invention as encompassed by formula (II): [Cha 7 ]hPTH(1-34)NH 2 ; [Cha 11 ]hPTH(1-34)NH 2 ; [Cha 15 ]hPTH(1-34)NH 2 ; [Cha 7 11 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Nle 8 18 , Tyr 34 ]hPTH(1-34) NH 2 ; [Cha 23 ]hPTH(1-34)NH 2 ; [Cha 24 ]hPTH(1-34)NH 2 ; [Nle 8 18 , Cha 27 ; ]hPTH(1-34)NH 2 ; [Cha 28 ]hPTH(1-34)NH 2 ; [Cha 31 ]hPTH(1-34)NH 2 ; [Cha 27 ]hPTH(1-34)NH 2 ; [Cha 27 29 ]hPTH(1-34)NH 2 ; [Cha 28 ]bPTH(1-34)NH 2 ; [Cha 28 ]rPTH(1-34)NH 2 ; [Cha 24 28 31 ]hPTH(1-34)NH 2 ; [Aib 15 ]hPTH(1-34)NH 2 ; [Aib 19 ]hPTH(1-34)NH 2 ; [Aib 34 ]hPTH(1-34)NH 2 ; [Aib 16 19 ]hPTH(1-34)NH 2 ; [Aib 16 19 34 ]bPTH(1-34)NH 2 ; [Aib 16 34 ]hPTH(1-34)NH 2 ; [Aib 19 34 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Nle 8 18 , Aib 16 19 , Tyr 34 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Nle 8 18 31 , Aib 16 19 , Tyr 34 ]hPTH(1-34)NH 2 ; [Cha 7 , Aib 16 ]hPTH(1-34)NH 2 ; [Cha 11 , Aib 16 ]hPTH(1-34) 2 ; [Cha 7 , Aib 34 ]hPTH(1-34)NH 2 ; [Cha 11 , Aib 34 ]hPTH(1-34)NH 2 ; [Cha 27 , Aib 15 ]hPTH(1-34)NH 2 ; [Cha 27 , Aib 34 ]hPTH(1-34)NH 2 ; [Cha 28 , Aib 16 ]hPTH(1-34)NH 2 ; [Cha 28 , Aib 34 ]hPTH(1-34)NH 2 ; [Nle 31 ]hPTH(1-34)NH 2 ; [hArg 27 ]hPTH(1-34)NH 2 ; [Dap 1 , Nle 8 18 , Tyr 34 ]hPTH(1-34)NH 2 ; [NLE 31 ]bPTH(1-34)NH 2 ; [Nle 31 ]rPTH(1-34)NH 2 ; [hArg 27 ]bPTH(1-34)NH 2 ; [hArg 27 ]rPTH(1-34)NH 2 ; [Cha 7 11 , Aib 19 , Lys 30 ]hPTH(1-34)NH 2 ; [Aib 12 ]hPTH(1-34)NH 2 ; [Cha 24 28 31 , Lys 30 ]hPTH(1-34)NH 2 ; [Cha 28 31 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Nle 8 18 , Aib 34 ]hPTH(1-34)NH 2 ; [Aib 3 ]hPTH(1-34)NH 2 ; [Cha 8 ]hPTH(1-34)NH 2 ; [Cha 15 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Aib 19 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Aib 16 ]hPTH(1-34)NH 2 ; [Aib 17 ]hPTH(1-34)NH 2 ; [Cha 6 ]hPTH(1-34)NH 2 ;[Cha 7 11 15 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Nle 8 18 , Aib 19 , Tyr 34 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Nle 8 18 , Aib 19 , Lys 30 , Tyr 34 ]hPTH(1-34)NH 2 ; [Cha 7 11 15 ]hPTH(1-34)NH 2 ; [Aib 17 ]hPTH(1-34)NH 2 ; [Cha 7 11 , Leu 27 ]hPTH(1-34) NH 2 ; [Cha 7 11 15 , Leu 27 ]hPTH(1-34)NH 2 ; [Cha 7 11 27 ]hPTH(1-34)NH 2 ; [Cha 7 11 15 27 ]hPTH (1-34)NH 2 ; [Trp 15 ]hPTH(1-34)NH 2 ; [Nal 15 ]hPTH(1-34) NH 2 ; [Trp 15 , Cha 23 ]hPTH(1-34)NH 2 ; [Cha 15 23 ]hPTH(1-34)NH 2 ; [Phe 7 11 ]hPTH(1-34)NH 2 ; [Nal 7 11 ]hPTH(1-34)NH 2 ; [Trp 7 11 ]hPTH (1-34)NH 2 ; [Phe 7 11 15 ]hPTH(1-34) NH 2 ; [Nal 7 11 15 ]hPTH(1-34)NH 2 ; [Trp 7 11 15 ]hPTH(1-34)NH 2 ; and [Tyr 7 11 15 ]hPTH(1-34)NH 2 .

The following are specific examples of peptides encompassed by one or more of formulas (III) to (V), hereinabove: [Cha 7 ]hPTHrP(1-34)NH 2 ; [Cha 11 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 ]hPTHrP(1-34)NH 2 ; [Aib 16 , Tyr 34 hPTHrP(1-34)NH 2 ; [Aib 19 ]hPTHrP(1-34)NH 2 ; [Aib 16 19 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 , Aib 19 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Lys 28 27 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 23 , Glu 25 29 , Leu 28 31 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Lys 23 26 30 , Leu 26 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Lys 26 , Cha 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 28 , Leu 23 28 31 , Lys 25 Aib 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 31 , Lys 26 28 30 ]hPTHrP(1-34) NH 2 ; [Cha 22 23 24 27 28 31 , Glu 26 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Cha 23 24 28 31 , Lys 26 27 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Cha 23 24 27 31 , Lys 26 28 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Lys 23 26 30 , Cha 24 27 28 31 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 27 30 ] hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 31 , Glu 25 29 , Lys 26 28 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Lys 23 26 30 , Glu 25 29 , Leu 25 31 ]hPHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 26 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 , Aib 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 25 27 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Lys 23 26 30 , Leu 28 31 , Aib 29 ] hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 31 , Lys 26 28 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 27 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 22 23 , Glu 25 29 , Leu 28 31 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 , Glu 22 25 29 , Lys 23 26 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 , Glu 22 25 29 , Leu 23 31 , Lys 26 28 30 ] hPTHrP(1-34)NH 2 ; [Cha 7 11 , Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 11 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 , Aib 30 ]hPTHrP(1-34)NH 2 ; [Cha 15 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 30 ]hPTHrP(1-34) NH 2 ; [Cha 15 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 15 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 27 30 ]hPTHrP(1-34)NH 2 ; [Cha 15 22 23 , Glu 25 29 , Leu 28 31 , Lys 26 30 ]hPTHrP(1-34) NH 2 ; [Cha 15 , Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 15 , Glu 22 25 29 , Lys 23 25 30 , Leu 28 31 ]hPTHrP(1-34) NH 2 ; [Cha 15 , Glu 22 25 29 , Leu 23 28 31 , Lys 25 , Aib 30 ] hPTHrP(1-34)NH 2 ; [Cha 15 , Glu 22 28 29 , Leu 23 31 , Lys 26 28 30 ]hPTHrP(1-34)NH 2 ; [Cha 15 30 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 ]hPTHrP(1-34)NH 2 ; [Cha 7 8 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 8 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 27 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 8 22 23 , Glu 25 29 , Leu 28 31 , Lys 26 30 ] hPTHrP (1-34)NH 2 ; [Cha 7 8 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 30 ] hPTHrP(1-34)NH 2 ; [Cha 7 8 , Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 26 30 ]hPTHrP(1-34) NH 2 ; [Cha 7 8 , Glu 22 25 29 , Lys 23 26 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Cha 7 8 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 , Aib 30 ] hPTHrP(1-34)NH 2 ; [Cha 7 8 , Glu 22 25 29 , Leu 23 31 , Lys 26 28 30 ]hPTHrP(1-34)NH 2 ; [Cha 7 8 30 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 ]hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 22 , Met 8 , Asn 10 , His 14 , Leu 23 28 31 , Glu 25 25 , Lys 26 30 ]hPTHrP(1-34) NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 , Met 8 , Asn 10 , His 14 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 27 30 ]hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 , Met 8 , Asn 10 , His 14 , Glu 22 25 29 , Leu 23 31 , Lys 26 28 30 ]hPTHrP(1-34)NH 2 ; Ser 1 , Ile 5 , Cha 7 11 , Met 8 , Asn 10 , His 14 , Glu 22 25 29 , Lys 23 26 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 , Met 8 , Asn 10 , His 14 , Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 26 30 ]hPTHrP(1-34) NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 , Met 8 , Asn 10 , His 14 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 , Aib 30 ] PTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 22 23 , Met 8 , Asn 10 , His 14 , Glu 25 29 , Leu 28 31 , Lys 26 30 ]hPTHrP(1-34) NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 15 , Met 8 , Asn 10 , His 14 ]hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 , His 14 , Aib 18 ]hPTHrP (1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 28 31 , His 14 , Cha 22 23 , Glu 25 29 , Lys 26 30 ]hPTHrP (1-34)NH 2 ; [Ser 1 , Ile 5 , Cha 7 11 , Met 8 , Asn 10 , His 14 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 30 ]hPTHrP (1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , His 14 , Cha 15 , Glu 22 25 29 , Leu 23 28 31 , Lys 26 30 ]hPTHrP (1-34)NH 2 ; [Ser 1 , Ile 5 , Cha 7 8 , Asn 10 , His 14 , Glu 22 25 29 , Leu 23 25 31 , Lys 26 30 ]hPTHrP (1-34)NH 2 ;[Glu 22 25 29 , Leu 23 28 31 , Lys 24 26 30 ]hPTHrP(1-34)NH 2 ; [Aib 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Aib 25 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Aib 26 , Lys 30 ]hPTHrP (1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 , Lys 26 30 31 ] hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 23 28 31 , His 14 , Cha 22 , Glu 25 29 , Lys 28 30 ] hPTHrP(2-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 28 31 , His 14 , Glu 22 25 29 , Lys 23 26 30 ]PTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 23 28 31 , His 14 , Glu 22 25 29 , Lys 26 27 30 ] hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 23 31 , His 14 , Glu 22 25 29 , Lys 25 28 30 ] hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 23 28 31 , His 14 , Glu 22 25 , Aib 29 , Lys 26 30 ] hPTHrP(1-34)NH 2 ; [Ser 1 , Ile 5 , Met 8 , Asn 10 , Leu 11 23 28 31 , His 14 , Glu 22 25 29 , Lys 25 , Aib 30 ] hPTHrP(1-34)NH 2 ; or [Ser 1 , Ile 5 , Met 8 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Ahc 23 , Lys 26 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 26 Leu 23 28 31 , Lys 26 30 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 Leu 23 28 , Lys 26 30 , Aib 29 , Ahc 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 Cha 23 , Lys 26 30 , Leu 28 31 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 Cha 23 , Lys 26 30 , Leu 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 Cha 23 , Lys 26 30 , Aib 29 ]hPTHrP (1-34)NH 2 ; [Ahc 22 , Leu 23 28 31 , Glu 25 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 26 , Aib 29 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Cha 23 , Lys 26 30 , Aib 29 , Leu 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Ahc 24 , Lys 26 30 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 31 , Lys 26 30 , Ahc 28 , Aib 29 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 , Leu 23 28 31 , Lys 28 , Aib 29 30 ] hPTHrP (1-34)NH 2 ; [Aib 22 29 , Leu 23 28 31 , Glu 25 , Lys 26 30 ]hPTHrP(1-34) NH 2 ; [Glu 22 25 , Leu 23 28 31 , Aib 28 29 , Lys 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Ahc 23 , Glu 25 29 , Lys 26 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Ahc 24 , Glu 25 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 30 , Ahc 27 ]hPThrP(1-34)NH 2 ; [Cha 22 , Leu 23 31 , Glu 25 29 , Lys 26 30 , Ahc 28 ]hPTHrP(1-34)NH 2 ; [Cha 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 , Leu 28 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Cha 22 23 , Glu 25 29 , Lys 26 30 , Leu 31 ]hPTHrP (1-34)NH 2 ; [Cha 22 , Leu 23 28 , Glu 25 29 , Lys 26 30 , Ahc 31 ]hPTHrP(1-34)NH 2 ; [Cha 22 23 , Glu 25 29 , Lys 26 30 , Leu 31 ]hPTHrP(1-34)NH 2 ; [Cha 22 23 , Glu 25 29 , Lys 26 30 , Leu 28 ]hPTHrP(1-34)NH 2 ; [Cha 22 23 , Glu 25 29 , Lys 26 30 ] hPTHrP(1-34)NH 2 ; [Glu 22 , Leu 23 28 31 , Aib 25 29 , Lys 26 30 ]hPTHrP(1-34) NH 2 ; [Glu 22 29 , Ahc 23 , Aib 25 , Lys 26 30 , Leu 28 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 31 , Aib 25 , Lys 26 30 , Glu 29 ] hPTHrP(1-34)NH 2 ; [Aib 22 25 , Leu 23 28 31 , Lys 26 30 , Glu 29 ]hPTHrP (1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Ahc 24 , Aib 25 , Lys 26 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Aib 25 26 , Lys 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Aib 25 , Lys 25 30 , Ahc 27 ] hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 31 , Aib 25 , Lys 25 30 , Ahc 28 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 29 , Leu 23 28 , Aib 25 , Lys 26 30 , Ahc 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Aib 25 30 , Lys 26 ] hPTHrP(1-34)NH 2 ; [Glu 22 29 , Leu 23 28 31 , Aib 25 , Lys 26 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Cha 23 , Aib 25 , Lys 26 30 , Leu 28 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Cha 23 , Aib 25 , Lys 26 30 , Leu 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 29 , Cha 23 , Aib 25 , Lys 26 30 ] hPTHrP(1-34)NH 2 ; [Glu 22 29 , Cha 23 , Aib 25 , Lys 26 30 , Leu 28 ]hPTHrP(1-34) NH 2 ; [Glu 22 25 29 , Cha 23 , Lys 26 , Leu 28 31 , Aib 30 ] hPTHrP (1-34)NH 2 ; [Glu 22 25 29 , Cha 23 , Lys 26 , Aib 30 , Leu 31 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Cha 23 , Lys 26 , Aib 30 ]hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Cha 23 ; Lys 26 , Leu 28 , Aib 30 ]hPTHrP(1-34)Nh 2 ; [Glu 22 25 29 , Leu 23 28 31 , Lys 25 , Ahc 27 , Aib 30 ] hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Ahc 24 , Lys 26 , Aib 30 ]hPTHrP (1-34)NH 2 ; [Ahc 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 , Aib 30 ]hPTHrP(1-34)NH 2 ; [Aib 22 30 , Leu 23 28 31 , Glu 25 29 , Lys 26 ] hPTHrP(1-34)NH 2 ; [Gky 22 28 , Lys 26 30 31 , Aib 29 ]hPTHrP(1-34) NH 2 ; [Cha 22 , Leu 23 28 , Glu 25 29 , Lys 26 30 31 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 , Glu 25 29 , Lys 25 30 31 ] hPTHrP(1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 , Lys 26 30 31 , Ahc 30 ]hPTHrP (1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 31 , Lys 26 , Ahc 30 ]hPTHrP(1-34)NH 2 ; [Ahc 22 , Leu 23 28 31 , Glu 25 29 , Lys 26 30 ]hPTHrP (1-34)NH 2 ; [Glu 22 25 29 , Leu 23 28 , Lys 26 30 31 , Ahc 27 ]hPTHrP(1-34)NH 2 .

In another aspect, the present invention is directed to a method of treating osteoporosis in a patient in need thereof, which comprises administering to said patient a compound of formula (I), (II), (III), (IV) or (V) or a pharmaceutically acceptable salt thereof, as defined hereinabove.

In another aspect, the present invention is directed to a method of treating osteoporosis in a patient in need thereof, which comprises administering to said patient a combination of a bisphosphonate or calcitonin and a compound of formula (I), (II), (III), (IV) or (V) or a pharmaceutically acceptable salt thereof, as defined hereinabove.

In another aspect, the present invention is directed to a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV) or (V) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

In another aspect, the present invention is directed to a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IV) or (V) or a pharmaceutically acceptable salt thereof as defined hereinabove, a bisphosphonate or calcitonin and a pharmaceutically acceptable carrier or diluent.

In another aspect, the present invention is directed to a method of treating osteoporosis in a patient in need thereof, which comprises administering to said patient a peptide of the formula [Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention is directed to a method of treating osteoporosis in a patient in need thereof, which comprises administering to said patient a combination of a bisphosphonate or calcitonin and a peptide of the formula [Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 28 30 ]hPTHrP(1-34)NH 2 or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention is directed to a pharmaceutical composition comprising a peptide of the formula [Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 26 30 ]hPTHrP(1-34)NH 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or diluent.

In another aspect, the present invention is directed to a pharmaceutical composition comprising a peptide of the formula [Glu 22 25 , Leu 23 28 31 , Aib 29 , Lys 26 30 ]hPTHrP(1-34(NH 2 or a pharmaceutically acceptable salt thereof, a bisphosphonate or calcitonin, and a pharmaceutically acceptable carrier or diluent.

In another aspect, the present invention is directed to a method of treating osteoporosis in a patient in need thereof, which comprises administering to said patient a peptide of the formula (VI):

wherein

A 1 is Ala, Ser, or Dap; A 3 is Ser or Aib; A 5 is His, Ile, Acc, or Cha; A 7 is Leu, Cha, Nle, β-Nal, Trp, Pal, Acc, Phe, or p-X-Phe in which X is OH, a halogen, or CH 3 ; A 8 is Leu, Met, Acc, or Cha; A 10 is Asp or Asn; A 11 is Lys, Leu, Cha, Acc, Phe, or β-Nal; A 12 is Gly, Acc, or Aib; A 14 is Ser or His; A 15 is Ile, Acc, or Cha; A 16 is Gln or Aib; A 17 is Asp or Aib; A 18 is Leu, Aib, Acc, or Cha; A 19 is Arg or Aib; A 22 is Phe, Glu, Aib, Acc, or Cha; A 23 is Phe, Leu, Lys, Acc, or Cha; A 24 is Leu, Lys, Acc, or Cha; A 25 is His, Lys, Aib, Acc, or Glu; A 26 is His, Aib, Acc, or Lys; A 27 is Leu, Lys, Acc, or Cha; a 28 is Ile, Leu, Lys, Acc, or Cha; A 29 is Ala, Glu, Acc, or Aib; A 30 is Glu, Leu, Nle, Cha, Aib, Acc, or Lys; A 31 is Ile, Leu, Cha, Lys, Acc, or deleted; A 32 is His or deleted; A 33 is Thr or deleted; A 34 is Ala or deleted; each of R 1 and R 2 is, independently, H, C 1-12 alkanyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 , hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; or one and only one of R 1 and R 2 is COE 1 in which E 1 is C 1-12 alkyl, C 2-12 alkyl, C 2-12 alkenyl, C 7-20 phenylalkyl, C 11-20 naphthylalkyl, C 1-12 hydroxyalkyl, C 2-12 hydroxyalkenyl, C 7-20 hydroxyphenylalkyl, or C 11-20 hydroxynaphthylalkyl; and R 3 is OH, NH 2 , C 1-12 alkoxy, or NH—Y—CH 2 —Z in which Y is a C 1-12 hydrocarbon moiety and Z is H, OH, CO 2 H or CONH 2 ;

provided that at least one of A 5 , A 7 , A 8 , A 11 , A 12 , A 15 , A 18 , A 22 , A 23 , A 24 , A 25 , A 26 , A 27 , A 28 , A 29 , A 30 , or A 31 is Acc; or a pharmaceutically acceptable salt thereof.

In another aspect, the present invention is directed to a method of treating osteoporosis in a patient in need thereof, which comprises administering to said patient a combination of a bisphosphonate or calcitonin and a peptide of formula (VI), as defined hereinabove.

In another aspect, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a peptide of formula (VI), as defined hereinabove.

In another aspect, the present invention is directed to a pharmaceutical composition comprising a bisphosphonate or calcitonin, a pharmaceutically acceptable carrier or diluent, and a peptide of formula (VI), as defined hereinabove.

With the exception of the N-terminal amino acid, all abbreviations (e.g. Ala or A 1 ) of amino acids in this disclosure stand for the structure of —NH—CH(R)—CO—, wherein R is a side chain of an amino acid (e.g. CH 3 for Ala). For the N-terminal amino acid, the abbreviation stands for the structure of ═N—CH(R)—CO—, wherein R is a side chain of an amino acid. β-Nal, Nle, Dap, Cha, Nva, Amp, Pal, Ahc, and Aib are the abbreviations of the following α-amino acids; β-(2-naphthyl)alanine, norleucine, α,β-diaminopropionic acid, cyclohexylalanine, norvaline, 4-amino-phenylalanine, β-(3-pyridinyl)alanine. 1-amino-1-cyclo-hexanecarboxylic acid, and α-aminoisubutyric acid, respectively. What is meant by Acc is an amino acid selected from the group of 1-amino-1-cyclopropanecarboxylic acid:

1-amino-1-cyclobutanecarboxylic acid; 1-amino-1-cyclopentanecarboxylic acid; 1-amino-1-cyclohexanecarboxylic acid; 1-amino-1-cycloheptanecarboxylic acid; 1-amino-1-cyclooctanecarboxylic acid; 1-amino-1cyclononanecarboxylic acid. In the above formula, hydroxyalkyl, hydroxyphenyl-alkyl, and hydroxynaphthylalkyl may contain 1-4 hydroxy substituents. Also, COE 1 stands for —C═O.E 1 . Examples of —C═O.E 1 include, but are not limited to, acetyl and phenylpropionyl.

A peptide of this invention is also denoted herein by another format, e.g, [Ahc 7 11 ]hPTH(1-34)NH 2 , with the substituted amino acids from the natural sequence placed between the second set of brackets (e.g., Ahc 7 for Leu 7 , and Ahc 11 for Leu 11 in hPTH). The abbreviation hPTH stands for human PTH, hPTHrP for human PTHrP, rPTH for rat PTH, and bPTH for bovine PTH. The numbers between the parentheses refer to the number of amino acids present in the peptide (e.g., hPTH(1-34) is amino acids 1 through 34 of the peptide sequence for human PTH). The sequences for hPTH(1-34), hPTHrP(1-34), bPTH(1-34), and rPTH(1-34) are listed in Nissenson, et al., Receptor, 3:193 (1993). The designation “NH 2 ” in PTH(1-34)NH 2 indicates that the C-terminus of the peptide is amidated. PTH(1-34), on the other hand, has a free acid C-terminus.

Each of the peptides of the invention is capable of stimulating the growth of bone in a subject (i.e., a mammal such as a human patient). Thus, it is useful in the treatment of osteoporosis and bone fractures when administered alone or concurrently with antiresorptive therapy, e.g., bisphosphonates and calcitonin.

The peptides of this invention can be provided in the form of pharmaceutically acceptable salts. Examples of such salts include, but are not limited to, those formed with organic acids (e.g., acetic, lactic, maleic, citric, malic, ascorbic, succinic, benzoic, methanesulfonic, toluenesulfonic, or pamoic acid), inorganic acids (e.g., hydrochloric acid, sulfuric acid, or phosphoric acid), and polymeric acids (e.g., tannic acid, carboxymethyl cellulose, polylactic, polyglycolic, or copolymers of polylactic-glycolic acids).

A therapeutically effective amount of a peptide of this invention and a pharmaceutically acceptable carrier substance (e.g., magnesium carbonate, lactose, or a phospholipid with which the therapeutic compound can form a micelle) together form a therapeutic composition (e.g., a pill, tablet, capsule, or liquid) for administration (e.g., orally, intravenously, transdermally, pulmonarily, vaginally, subcutaneously, nasally, iontophoretically, or by intratracheally) to a subject. The pill, tablet, or capsule that is to be administered orally can be coated with a substance for protecting the active composition from the gastric acid or testinal enzymes in the stomach for a period of time sufficient to allow it to pass undigested into the small intestine. The therapeutic composition can also be in the form of a biodegradable or nonbiodegradable sustained release formulation for subcutaneous or intramuscular administration. See, e.g., U.S. Pat. Nos. 3,773,919 and 4,767,628 and PCT Application No. WO 94/15587. Continuous administration can also be achieved using an implantable or external pump (e.g., INFUSAID™ pump). The administration can also be conducted intermittently, e.g., single daily injection, or continuously at a low dose, e.g., sustained release formulation.

The dose of a peptide of the present invention for treating the above-mentioned diseases or disorders varies depending upon the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian.

Also contemplated within the scope of this invention is a peptide covered by the above generic formula for use in treating diseases or disorders associated with deficiency in bone growth or the like, e.g., osteoporosis or fractures.

Other features and advantages of the present invention will be apparent from the detailed description and from the claims.

Based on the description herein, the present invention can be utilized to its fullest extent. The following specific examples are to be construed as merely illustrative, and should not be construed as a limitation of the remainder of the disclosure in any way whatsoever. Further, all publications cited herein are incorporated by reference.

Structure

PTH(1-34) and PTHrP(1-34) have been reported to have two amphophilic alpha helical domains. See, e.g., Barden, et al., Biochem., 32:7126 (1992). The first “-helix is formed between amino acid residues 4 through 13, while the second “-helix is formed between amino acid residues 21 through 29. Some peptides of this invention contain the substitution of Acc for one or more residues within or near these two regions of PTH(1-34) and PTHrP(1-34), e.g., Ahc 7 and Ahc 11 within the first “-helix or Ahc 27 and Ahc 28 within the second “-helix; or Cha 7 and Cha 11 within the first α-helix or Cha 27 and Cha 28 within the second α-helix.

Synthesis

The peptides of the invention can be prepared by standard solid phase synthesis. See, e.g., Stewart, J. M., et al., Solid Phase Synthesis (Pierce Chemical Co., 2d ed. 1984) The following is a description of how [Glu 22 25 , Leu 23 28 , Lys 26 30 , Aib 29 , Ahc 31 ]hPTH(1-34)NH 2 was prepared. Other peptides of the invention can be prepared in an analogous manner by a person of ordinary skill in the art.

1-[N-tert-Butoxycarbonyl-amino]-1-cyclohexane-carboxylic acid (Boc-Ahc-OH) was synthesized as follows:

19.1 g (0.133 mol) of 1amino-1cyclohexanecarboxylic acid (Acros Organics, Fisher Scientific, Pittsburgh, Pa.) was dissolved in 200 ml of dioxane and 100 ml of water. To it was added 67 mg of 2N NaOH. The solution was cooled in an ice-water bath. 32.0 g (0.147 mol) of di-tert-butyl-dicarbonate was added to this solution. The reaction mixture was stirred overnight at room temperature. Dioxane was then removed under reduced pressure. 200 ml of ethyl acetate was added to the remaining aqueous solution. The mixture was cooled in an ice-water bath. The pH of the aqueous layer was adjusted to about 3 by adding 4N HCl. The organic layer was separated. The aqueous layer was extracted with ethyl acetate (1×100 ml). Two organic layers were combined and washed with water (2×150 ml), dried over anhydrous MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was recrystallized in ethyl acetate/hexanes. 9.2 g of a pure product was obtained. 29% yield. Other protected Acc amino acids can be prepared in an analogous manner by a person or ordinary skill in the art.

The peptide was synthesized on an Applied Biosystems (Foster City, Calif.) model 430A peptide synthesizer which was modified to do accelerated Boc-chemistry solid phase peptide synthesis. See Schnoize, et al., Int. J. Peptide Protein Res., 90:180 (1992). 4-Methylbenz-hydrylamine (MBHA) resin (Peninsula, Belmont, Calif.) with the substitution of 0.93 mmol/g was used. The Boc amino acis (Bachem, Calif., Torrance, Calif.; Nova Biochem., LaJolla, Calif.) were used with the following side chain protection. Boc-Ala-OH, Boc-Arg(Tos)-OH, Boc-Asp(OcHex)-OH, Boc-Glu(OcHex)-OH, Boc-His(DNP)-OH, Boc-Val-OH, Boc-Leu-OH, Boc-Gly-OH, Boc-Gln-OH, Boc-IIe-OH, Boc-Lys(2ClZ)-OH, Boc-Ahc-OH, Boc-Thr(Bzl)-OH, Boc-Ser(Bzl)-OH; and Boc-Aib-OH. The synthesis was carried out on a 0.14 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2×1 min. Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 l mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 min except for the Boc-Aib-OH, and its following residue Boc-Leu-OH, and Boc-Ahc-OH, and its following residue Boc-Lys(2 Clz)-OH, wherein the coupling times for these four residues were 2 hrs.

At the end of the assembly of the peptide chain, the resin was treated with a solution of 20% mercaptoethanol/10% DIEA in DMF for 2×30 min. to remove the DNP group on the His side chain. The N-terminal Boc group was then removed by treatment with 100% TFA for 2×2 min. The partially-deproteted peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (24 mg) at OEC for 75 min. HF was removed by a flow of nitrogen. The residue was washed with ether (6×10 mL) and extracted with 4N HOAc (6×10 mL).

The peptide mixture in the aqueous extract was purified on a reversed-phase preparative high pressure liquid chromatography (HPLC) using a reversed phase VYDAC™ C 18 column (Nest Group, Southborough, Mass.). The column was eluted with a linear gradient (10% to 45% of solution B over 130 min.) at a flow rate of 10 mL/min (Solution A=0.1% aqueous TFA. Solution B=acetonitrile containing 0.1% of TFA). Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 85 mg of a white solid was obtained. Purity was >99% based on analytical HPLC analysis. Electro-spray mass spectrometer analysis gave the molecular weight at 3972.4 (in agreement with the calculated molecular weight of 3972.7).

The synthesis and purification of [Cha 22 , Leu 23 28 31 , Glu 25 , Lys 26 30 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 was carried out in the same manner as the above synthesis of [Glu 22 25 , Leu 23 28 , Lys 26 30 , Aib 29 , Ahc 31 ]hPTHrP(1-34)NH 2 . The protected amino acid Boc-Cha-OH was purchased from, Bachem, Calif. The purity of the final product was >99%, and the electron-spray mass spectrometer gave the molecular weight at 3997.2 (calculated molecular weight is 3996.8).

The following is a description of how [Aib 34 ]hPTH(1-34)NH 2 was prepared. The peptide, [Aib 34 ]hPTH(1-34)NH 2 , was synthesized on an Appiled Biosystems (Foster City, Calif.) model 430A peptide synthesizer which was modified to do accelerated Boc-chemistry solid phase peptide synthesis. See Schnoize, et al., Int. J. Peptide Protein Res,. 90:180 (1992). 4-Methylbenz-hydrylamine (MBHA) resin (Peninsula, Belmont, Calif.) with the substitution of 0.93 mmol/g was used. The Boc amino acids (Bachem, Calif., Torrance, Calif.; Nova Biochem., Lajolla, Calif.) were used with the following side chain protection: Boc-Arg(Tos)-OH, Boc-Asp (OcHxl)-OH, Boc-Asn(Xan)-OH, Boc-Glu(OcHxl)-OH, Boc-His(DNP)-OH, Boc-Asn-GH, Boc-Val-OH, Boc-Leu-OH, Boc-Ser-OH, Boc-Gly-OH, Boc-Met-OH, Boc-Gln-OH, Boc-lle-OH. Boc-Lys(2ClZ)-OH, Boc-Ser(Bzl)-OH, and Boc-Trp(Fm)-OH. The synthesis was carried out on a 0.14 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2×1 min. Box amino acids (2.5 mmol) were pre-activated with HBTU (2.1 mmol) and DIEA (1.0 mL) n 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 min except for the Boc-Aib-OH and the following residue, Boc-Asn(Xan)-OH, wherein the coupling times were 20 min.

At the end of the assembly of the peptide chain, the resin was treated with a solution of 20% mercaptoethanol/10% DIEA in DMF for 2×30 min. to remove the DNP group on the His side chain. The N-terminal Boc group was then removed by treatment with 100% TFA for 2×2 min. After neutralization of the peptide-resin with 10% DIEA in DMF (1×1 min.), the formyl group on the side chain of Trp was removed by treatment with a solution of 15% ethanolamine/15% water/70% DMF for 2×30 min. The partially-deprotected peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole at 0° C. for 75 min. HF was removed by a flow of nitrogen. The residue was washed with ether (6×10 ) mL) and extracted with 4N HOAc (6×10 mL).

The peptide mixture in the aqueous extract was purified on a reversed-phase preparative high pressure liquid chromatography (HPLC) using a reversed phase VYDAC™ C 18 column (Nest Group, Southborough, Mass.). The column was eluted with a linear gradient (10% to 45% of solution B over 130 min.) at a flow rate of 10 mL/min (Solution A=0.1% aqueous TFA; Solution B=acetonitrile containing 0.1% of TFA). Fractions were collected and checked on analytic HPLC. Those containing pure product were combined and lyophilized to dryness. 62.3 mg of a white solid was obtained. Purity was >99% based on analytical HPLC analysis. Electro-spray mass spectrometer analysis gave the molecular weight at 4054.7 (in agreement with the calculated molecular weight of 4054.7).

The synthesis and purification of [Cha 7 11 ]hPTH(1-34)NH 2 was carried out in the same manner as the above synthesis of [Aib 34 ]hPTH(1-34)NH 2 . The protected amino acid Boc-Cha-OH was purchased from Bachem, Calif. The purity of the final product was >98%, and the electron-spray mass spectrometer gave the molecular weight at 4197.0 (calculated molecular weight is 4196.9).

The following is a description of how [Glu 22 25 , Leu 23 28 , Lys 26 30 , Aib 29 , Ahc 31 ]hPTH(1-34)NH 2 was prepared. Other peptides of the invention can be prepared in an analogous manner by a person of ordinary skill in the art.

1-[N-tert-Butoxycarbonyl-amino]-1-cyclohexane-carboxylic acid (Boc-Ahc-OH) was synthesized as follows.

19.1 g (0.133 mol) of 1-amino-1-cyclohexanecarboxylic acid (Acros Organics, Fisher Scientific, Pittsburgh, Pa.) was dissolved in 200 ml of dioxane and 100 ml of water. To it was added 67 mg of 2N NaOH. The solution was cooled in an ice-water bath. 32.0 g (0.147 mol) of di-tert-butyl-dicarbonate was added to this solution. The reaction mixture was stirred overnight at room temperature. Dioxane was then removed under reduced pressure. 200 ml of ethyl acetate was added to the remaining aqueous solution. The mixture was cooled in an ice-water bath. The pH of the aqueous layer was adjusted to about 3 by adding 4N HCl. The organic layer was separated. The aqueous layer was extracted with ethyl acetate (1×100 ml). Two organic layers were combined and washed with water (2×150 ml), dried over anhydrous MgSO 4 , filtered, and concentrated to dryness under reduced pressure. The residue was recrystallized inn ethyl acetate/hexanes. 9.2 g of a pure product was obtained. 29% yield. Other protected Acc amino acids can be prepared in an analogous manner by a person or ordinary skill in the art.

The peptide was synthesized on an Applied Biosystems (Foster City, Calif.) model 430A peptide synthesizer which was modified to do accelerated Boc-chemistry solid phase peptide synthesis. See Schnoize, et al., Int. J. Peptide Protein Res., 90:180 (1992). 4-Methylbenz-hydrylamine (MBHA) resin (Peninsula, Belmont, Calif.) with the substitution of 0.93 mmol/g was used. The Boc amino acids (Bachem, Calif., Torrance, Calif.; Nova Biochem., LaJolla, Calif.) were used with the following side chain protection: Boc-Ala-OH, Boc-Arg(Tos)-OH, Boc-Asp(OcHex)-OH, Boc-Glu(OcHex)-OH, Box-His(DNP)-OH, Boc-Val-OH, Boc-Leu-OH, Boc-Gly-OH, Boc-Gln-OH, Boc-Lys(2ClZ)-OH, Boc-Ahc-OH, Boc-Thr(Bzl)-OH, Box-Ser(Bzl)-OH; and Box-Aib-OH. The synthesis was carried out on a 0.14 mmol scale. The Boc groups were removed by treatment with 100% TFA for 2×1 min. Boc amino acids (2.5 mmol) were pre-activated with HBTU (2.0 mmol) and DIEA (1.0 mL) in 4 mL of DMF and were coupled without prior neutralization of the peptide-resin TFA salt. Coupling times were 5 min except for the Boc-Aib-OH, and its following residue Boc-Leu-OH and Boc-Ahc-OH, and its following residue Boc-Lys(2Clz)-OH, wherein the coupling times for these four residues were 2 hours.

At the end of the assembly of the peptide chain, the resin was treated with a solution of 20% mercaptoethanol/10% DIEA in DMF for 2×30 min. to remove the DNP group on the His side chain. The N-terminal Boc group was then removed by treatment with 100% TFA for 2×2 min. The partially-deprotected peptide-resin was washed with DMF and DCM and dried under reduced pressure. The final cleavage was done by stirring the peptide-resin in 10 mL of HF containing 1 mL of anisole and dithiothreitol (24 mg) at 0° C. for 75 min. HF was removed by a flow of nitrogen. The residue was washed with ether (6×10 mL) and extracted with 4N HOAc (6×10 mL).

The peptide mixture in the aqueous extract was purified on a reversed-phase preparative high pressure liquid chromatography (HPLC) using a reversed phase VYDAC™ C 18 column (Nest Group, Southborough, Mass.). The column was eluted with a linear gradient (10% to 45% of solution B over 130 min.) at a flow rate of 10 mL/min (Solution A=0.1% aqueous TFA: Solution B=acetonitrile containing 0.1% of TFA). Fractions were collected and checked on analytical HPLC. Those containing pure product were combined and lyophilized to dryness. 85 mg of a white solid was obtained. Purity was >99% based on analytical HPLC analysis. Electro-spray mass spectrometer analysis gave the molecular weight at 3972.4 (in agreement with the calculated molecular weight of 3972.7).

The synthesis and purification of [Cha 22 , Leu 23 28 31 , Glu 25 , Lys 26 30 , Ahc 27 , Aib 29 ]hPTHrP(1-34)NH 2 was carried out in the same manner as the above synthesis of [Glu 22 25 , Leu 23 28 , Lys 26 30 , Aib 29 , Ahc 31 ]hPTHrP(1-34)NH 2 . The protected amino acid Boc-Cha-OH was purchased from Bachem, Calif. The purity of the final product was >99%, and the electron-spray mass spectrometer gave the molecular weight at 3997.2 (calculated molecular weight is 3996.8).

The full names for the abbreviations used above are as follows: Boc for t-butyloxycarbonyl, HF for hydrogen fluoride, Fm for formyl, Xan for xanthyl, Bzl for benzyl, Tos for tosyl, DNP for 2,4-dinitrophenyl, DMF for dimethylformamide, DCM for dichloromethane. HBTU for 2-(1H-Benzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate, DIEA for diisopropylethylamine, HOAc for acetic acid, TFA for trifluoroacetic acid, 2ClZ for 2-chlorobenzyloxycarbonyl, and OcHex for O-cyclohexyl.

The substituents R 1 and R 2 of the above generic formula may be attached to the free amine of the N-terminal amino acid by standard methods known in the art. For example, alkyl groups, e.g., C 1-12 alkyl, may be attached using reductive alkylation. Hydroxyalkyl groups, e.g., C 1-12 hydroxyalkyl, may also be attached using reductive alkylation wherein the free hnydroxy group is protected with a t-butyl ester. Acyl groups, e.g., may be attached by coupling the free acid, e.g., E 1 COOH, to the free amine of the N-terminal amino acid by mixing the completed resin with 3 molar equivalents of both the free acid and diisopropylcarbodiimide in methylene chloride for one hour and cycling the resulting resin through steps (a) to (f) in the above wash program. If the free acid contains a free hydroxy group, e.g., p-hydroxyphenylpropionic acid, then the coupling should be performed with an additional 3 molar equivalents of HOBT.

Other peptides of this invention can be prepared in an analogous manner by a person of ordinary skill in the art.

Functional Assays

A. Binding to PTH Receptor

The peptides of the invention were tested for their ability to bind to the PTH receptor present on SaOS-2 (human osteosarcoma cells). SaOS-2 cells (American Type Culture Collection, Rockville, Md.; ATCC #HTB 85) were maintained in RPMI 1640 medium (Sigma, St. Louis, Mo.) supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine at 3EC in a humidified atmosphere of 5% CO 2 in air. The medium was changed every three or four days, and the cells were subcultured every week by trypsinization.

SaOS-2 cells were maintained for four days until they had reached confluence. The medium was replaced with 5% FBS in RPMI 1640 medium and incubated for 2 hrs at room temperature with 10×10 4 cpm mono- 125 l-[Nle 8 18 , Tyr 34 (3- 125 l)] bPTH(1-34)NH 2 in the presence of a competing peptides of the invention at various concentrations between 10 −11 M to 10 −4 M. The cells were washed four times with ice-cold PBS and lysed with 0.1 M NaOH, and the radioactivity associated with the cells was counted in a scintillation counter. Synthesis of mono- 125 l-[Nle 8 18 , Tyr 34 (3- 125 l)]bPTH(1-34)NH 2 was carried out as described in Goldman, M. E., el al., Endocrinol., 123:1468 (1988).

The binding assay was conducted with various peptides of the invention and the Kd value (half maximal inhibition of binding of mono- 125 l-[Nle 8 18 , Tyr 34 (3- 125 l)]bPTH(1-34)NH 2 ) for each peptide was calculated.

As shown in Table I, all of the tested peptides had a high binding affinity for the PTH receptor on the SaOS-2 cell.

B. Stimulation of Adenylate Cyclase Activity

The ability of the peptides of the invention to induce a biological response in SaOS-2 cells were measured. More specifically, any stimulation of the adenylate cyclase was determined by measuring the level of synthesis of cAMP (adenosine 3′, 5′-monophosphate) as described previously in Rodan, et al., J. Clin. Invest. 72; 1511 (1983) and Goldman, et al., Endocrinol., 123:1468 (1988). Confluent SAOS-2 cells in 24 wells plates were incubated with 0.5.Cl [ 3 H]adenine (26.9 Cl/mmol, New England Nuclear, Boston, Mass.) in fresh medium at 37EC for 2 hrs, and washed twice with Hank's balanced salt solution (Gibco, Gaithersburg, Md.). The cells were treated with 1 mM IBMX [isobutylmethyl-xanthine, Sigma, St. Louis, Mo.] in fresh medium for 15 min, and the peptides of the invention were added to the medium to incubate for 5 min. The reaction was stopped by the addition of 1.2 M trichloroacetic acid (TCA) (Sigma, St. Louis, Mo.) followed by sample neutralizaton with 4N KOH. cAMP was isolated by the two-column chromatographic method (Salmon, et al., 1974, Anal. Biochem. 58, 541). The radioactivity was counted in a scintillation counter (Liquid Scintillation Counter 2200CA, PACKARD, Downers Grove, Ill.).

The respective EC 50 values (half maximal stimulation of adenylate cyclase) for the tested peptides were calculated and shown in Table I. All tested peptides were found to be potent stimulators of adenylate cyclase activity, which is a biochemical pathway indicative as a proximal signal for osteoblast proliferation (e.g., bone growth).

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.